Uropathogenic Escherichia coli (UPEC) are a major cause of urinary tract infections (UTI) and sepsis. Recently, a highly virulent clone of UPEC (E. coli ST131) that is resistant to multiple types of antibiotics has emerged worldwide. This project addresses the mechanisms by which E. coli ST131 can colonise the urinary tract and cause disease. The outcomes of this project will be a better understanding of how E. coli ST131 causes disease, and potentially new treatment regimes for UTI.
Functional And Genomic Analysis Of The Globally Disseminated Multidrug Resistant Escherichia Coli ST131 Clone
Funder
National Health and Medical Research Council
Funding Amount
$825,537.00
Summary
Uropathogenic Escherichia coli (UPEC) is a major cause of urinary tract infections (UTI) and sepsis. Recently, a highly virulent clone of UPEC (E. coli ST131) that is resistant to multiple types of antibiotics has emerged and spread worldwide. This project uses genomic and high-throughput functional analysis methods to understand E. coli ST131 virulence and resistance. The outcomes of the work will be a better understanding of how E. coli ST131 causes disease, and potentially new treatment regim ....Uropathogenic Escherichia coli (UPEC) is a major cause of urinary tract infections (UTI) and sepsis. Recently, a highly virulent clone of UPEC (E. coli ST131) that is resistant to multiple types of antibiotics has emerged and spread worldwide. This project uses genomic and high-throughput functional analysis methods to understand E. coli ST131 virulence and resistance. The outcomes of the work will be a better understanding of how E. coli ST131 causes disease, and potentially new treatment regimes for UTI.Read moreRead less
Understanding The Role Of The Two Major Bacterial Pathogens In The Upper And Lower Airways Of Indigenous Children With Chronic Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$743,282.00
Summary
Lung infections are a major disease burden worldwide. Indigenous Australians are affected more; adults with severe lung disease can die in their 30s and 40s. These diseases start early, yet no in-depth studies of bacteria causing lung infections in children have been done. Our expert team proposes to use existing lung fluids from nearly 500 children with chronic lung disease (58% Indigenous), and state-of-the-art laboratory methods, to inform the design of vaccines to prevent lung disease.